Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease
Abstract
OBJECTIVE: Dysfunction of mitochondrial DNA polymerase gamma (POLG) has been recently recognized as an important cause of inherited neurodegenerative diseases. We have reported dominant and recessive inheritance of parkinsonism, mitochondrial myopathy, and premature amenorrhea in five ethnically distinct families with POLG1 mutations. This prompted us to carry out a detailed analysis of the coding region and intron-exon boundaries of POLG1 in Finnish patients with idiopathic sporadic Parkinson disease (PD) and in nonparkinsonian controls. METHODS: The coding region of POLG1 was analyzed in 140 Finnish patients with PD and their 127 spouses as age- and ethnically matched controls. Further, we analyzed the intragenic CAG-repeat region of POLG1 in 126 additional patients with nonparkinsonian neurologic disorders and in 516 Finnish population controls. RESULTS: We found clustering of rare variants of the POLG1 CAG-repeat, encoding a polyglutamine tract, in Finnish patients with idiopathic PD as compared to their spouses (p = 0.003; OR 3.01, 95% CI 1.35 to 6.71), population controls (p = 0.001; OR 2.45, 95% CI 1.45 to 4.14), and patients with nonparkinsonian neurologic disorders (p = 0.05, OR 1.98, 95% CI 0.97 to 4.05). We found several amino acid substitutions, none of them associating with PD. These included a previously parkinsonism-associated POLG variant Y831C, found in one patient with PD, but also in five controls, suggesting that it is a neutral amino acid polymorphism. CONCLUSIONS: Our results suggest that POLG polyglutamine tract variants should be considered as a predisposing genetic factor in idiopathic sporadic Parkinson disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The A2492G substitution is probably a neutral polymorphism as it has a 1.1% frequency in controls.
“However, it was later determined that the substitution is probably a neutral polymorphism as it has a 1.1% frequency in controls (Luoma et al., 2007; Tiangyou et al., 2006).”
From Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases (2017) · cites this paper as Luoma et al., 2007
Rare variants in the CAG-repeat of Pol γ were found in patients with idiopathic PD.
“Lastly, Pol γ contains a polyglutamine tract in the N-terminal region encoded by a CAG-repeat and rare variants in the CAG-repeat were found in patients with idiopathic PD (Luoma et al., 2007).”
From Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases (2017) · cites this paper as Luoma et al., 2007
The citation lists haven’t been fetched yet
References 37 · Cited by 154
- Authors
- Luoma, P. T., Eerola, J., Ahola, S., Hakonen, A. H., Hellström, O., Kivistö, K. T., Tienari, P. J., & Suomalainen, A.
- Affiliations
- University of Helsinki (FI)
- From Research Program of Molecular Neurology, Biomedicum-Helsinki, Helsinki University, and Department of Neurology, Helsinki University Central Hospital (P.T.L, J.E., S.A., A.H.H., P.J.T., A.S.); Seinäjoki Central Hospital (O.H.); and Department of Pharmacological Sciences (K.T.K), Tampere University, Finland.
- Venue
- Neurology
- Published
- 2007-09-11
- Volume
- 69
- Issue
- 11
- Pages
- 1152-1159
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2055513768
- Cited by
- 154
- References
- 37
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 17 · 2021: 7 · 2020: 8 · 2019: 2 · 2018: 5 · 2017: 8 · 2016: 3 · 2015: 11 · 2014: 8 · 2013: 6 · 2012: 13
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Keywords
- Parkinson's disease, POLG1, mitochondrial DNA polymerase gamma, polyglutamine tract, CAG repeat polymorphism, genetic susceptibility, sporadic Parkinson disease, Finnish patients, amino acid substitutions, parkinsonism
- MeSH terms
- DNA Polymerase gamma, Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, DNA-Directed DNA Polymerase, DNA, Mitochondrial, Female, Genetic Markers, Genetic Testing, Genotype, Humans, Male, Middle Aged, Parkinson Disease, Peptides, Polymorphism, Genetic, Open Reading Frames, Trinucleotide Repeat Expansion, Genetic Predisposition to Disease, Mitochondrial Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review